Esperion delivered robust second quarter 2025 results, with total revenue increasing 12% year-over-year to $82.4 million, driven by a 42% surge in U.S. net product revenue. The company achieved its first quarter of operating income from ongoing business and expects sustainable profitability starting in Q1 2026. Key accomplishments include settlement agreements protecting intellectual property until 2040 and continued expansion of market access for its therapies.